Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD

NCT04500847 is registered in ClinicalTrials.gov with Butler Hospital as lead sponsor.

NCT NCT04500847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04500847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
Lead sponsor
Butler Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
December 17, 2021
Completion date
March 31, 2026
Enrollment
35 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, early onset, mild cognitive impairment, moderate dementia